FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W416868247> ?p ?o ?g. }

• W416868247 endingPage "2275" @default.
• W416868247 startingPage "2267" @default.
• W416868247 abstract "Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin treatment. This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients treated with statins. Long-term and short-term relationships of triglycerides to risk after ACS were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index. Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dal-OUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p < 0.001). The hazard ratio in the highest/lowest quintile (>175/≤80 mg/dl) was 1.61 (95% confidence interval: 1.34-1.94). There was no interaction of triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk increased across tertiles of baseline triglycerides (p = 0.03), with a hazard ratio of 1.50 (95% confidence interval: 1.05 to 2.15) in highest/lowest tertiles (>195/≤135 mg/dl). The relationship of triglycerides to risk was independent of low-density lipoprotein cholesterol in both studies. Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy. (A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome; NCT00658515)" @default.
• W416868247 created "2016-06-24" @default.
• W416868247 creator A5002746489 @default.
• W416868247 creator A5015234811 @default.
• W416868247 creator A5022674575 @default.
• W416868247 creator A5025177656 @default.
• W416868247 creator A5027482892 @default.
• W416868247 creator A5065063579 @default.
• W416868247 creator A5075595313 @default.
• W416868247 creator A5078246051 @default.
• W416868247 date "2015-06-01" @default.
• W416868247 modified "2023-10-03" @default.
• W416868247 title "Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins" @default.
• W416868247 cites W1976428272 @default.
• W416868247 cites W1981569117 @default.
• W416868247 cites W2006551863 @default.
• W416868247 cites W2009220054 @default.
• W416868247 cites W2014558113 @default.
• W416868247 cites W2019530645 @default.
• W416868247 cites W2036747551 @default.
• W416868247 cites W2052644460 @default.
• W416868247 cites W2053116400 @default.
• W416868247 cites W2054299101 @default.
• W416868247 cites W2071298734 @default.
• W416868247 cites W2096931626 @default.
• W416868247 cites W2104105057 @default.
• W416868247 cites W2108169164 @default.
• W416868247 cites W2113680815 @default.
• W416868247 cites W2114949449 @default.
• W416868247 cites W2118825330 @default.
• W416868247 cites W2124565608 @default.
• W416868247 cites W2124964328 @default.
• W416868247 cites W2127427274 @default.
• W416868247 cites W2142347023 @default.
• W416868247 cites W2143340286 @default.
• W416868247 cites W2149433053 @default.
• W416868247 cites W2159449551 @default.
• W416868247 cites W2160152341 @default.
• W416868247 cites W2169582126 @default.
• W416868247 cites W2170009139 @default.
• W416868247 cites W2170210469 @default.
• W416868247 cites W2578698803 @default.
• W416868247 cites W4232807629 @default.
• W416868247 doi "https://doi.org/10.1016/j.jacc.2015.03.544" @default.
• W416868247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26022813" @default.
• W416868247 hasPublicationYear "2015" @default.
• W416868247 type Work @default.
• W416868247 sameAs 416868247 @default.
• W416868247 citedByCount "200" @default.
• W416868247 countsByYear W4168682472015 @default.
• W416868247 countsByYear W4168682472016 @default.
• W416868247 countsByYear W4168682472017 @default.
• W416868247 countsByYear W4168682472018 @default.
• W416868247 countsByYear W4168682472019 @default.
• W416868247 countsByYear W4168682472020 @default.
• W416868247 countsByYear W4168682472021 @default.
• W416868247 countsByYear W4168682472022 @default.
• W416868247 countsByYear W4168682472023 @default.
• W416868247 crossrefType "journal-article" @default.
• W416868247 hasAuthorship W416868247A5002746489 @default.
• W416868247 hasAuthorship W416868247A5015234811 @default.
• W416868247 hasAuthorship W416868247A5022674575 @default.
• W416868247 hasAuthorship W416868247A5025177656 @default.
• W416868247 hasAuthorship W416868247A5027482892 @default.
• W416868247 hasAuthorship W416868247A5065063579 @default.
• W416868247 hasAuthorship W416868247A5075595313 @default.
• W416868247 hasAuthorship W416868247A5078246051 @default.
• W416868247 hasBestOaLocation W4168682471 @default.
• W416868247 hasConcept C126322002 @default.
• W416868247 hasConcept C134018914 @default.
• W416868247 hasConcept C164705383 @default.
• W416868247 hasConcept C207103383 @default.
• W416868247 hasConcept C2776839432 @default.
• W416868247 hasConcept C2777482532 @default.
• W416868247 hasConcept C2777698277 @default.
• W416868247 hasConcept C2777785093 @default.
• W416868247 hasConcept C2778163477 @default.
• W416868247 hasConcept C2778913445 @default.
• W416868247 hasConcept C2780221984 @default.
• W416868247 hasConcept C2780578515 @default.
• W416868247 hasConcept C44249647 @default.
• W416868247 hasConcept C500558357 @default.
• W416868247 hasConcept C511355011 @default.
• W416868247 hasConcept C555293320 @default.
• W416868247 hasConcept C71924100 @default.
• W416868247 hasConceptScore W416868247C126322002 @default.
• W416868247 hasConceptScore W416868247C134018914 @default.
• W416868247 hasConceptScore W416868247C164705383 @default.
• W416868247 hasConceptScore W416868247C207103383 @default.
• W416868247 hasConceptScore W416868247C2776839432 @default.
• W416868247 hasConceptScore W416868247C2777482532 @default.
• W416868247 hasConceptScore W416868247C2777698277 @default.
• W416868247 hasConceptScore W416868247C2777785093 @default.
• W416868247 hasConceptScore W416868247C2778163477 @default.
• W416868247 hasConceptScore W416868247C2778913445 @default.
• W416868247 hasConceptScore W416868247C2780221984 @default.
• W416868247 hasConceptScore W416868247C2780578515 @default.
• W416868247 hasConceptScore W416868247C44249647 @default.

• next